HUTCHMED (China) Limited American Depositary Shares HCM

HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.

• GlobeNewswire Inc. 28 sept

  HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

  HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.

  

• GlobeNewswire Inc. 27 sept

  HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

  HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and licensing agreement with GSK on September 3, 2026, granting GSK worldwide rights (excluding Greater China) for development and commercialization.

  

• GlobeNewswire Inc. 23 sept

  HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

  HUTCHMED announced that two Phase III studies evaluating the savolitinib and osimertinib combination for non-small cell lung cancer will be presented at ESMO Congress 2026 in Madrid. The SAFFRON global study and SANOVO China study both demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared to chemotherapy and osimertinib monotherapy, respectively. The all-oral, chemo-free combination has been selected for high-profile oral presentations including a Presidential Symposium.

  

• Zacks Investment Research 2 sept

  AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal

  AstraZeneca announced positive Phase III SANOVO study results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced NSCLC with MET overexpression. The combination also demonstrated encouraging overall survival improvements. These results could expand the clinical utility of the combination to first-line treatment settings.

  

• GlobeNewswire Inc. 30 ago

  HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

  HUTCHMED announced positive Phase III SANOVO trial results showing that ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) demonstrated statistically significant progression-free survival improvements and encouraging overall survival benefits in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China, extending the clinical value of the combination into the first-line setting.